• 1
    Armitage, J.O. (1992) Chemotherapy for non-Hodgkin's lymphoma. Current Opinion in Oncology, 4, 840 846.
  • 2
    Armitage, J.O. (1993) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023 1030.
  • 3
    Demirer, T., Rowley, S., Buckner, C.D., Appelbaum, F.R., Lilleby, K., Storb, R., Schiffman, K., Bensinger, W.I. (1995) Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. Journal of Clinical Oncology, 13, 1714 1719.
  • 4
    Fennelly, D., Schneider, H., Spriggs, D., Bengala, C., Hakes, T., Reich, L., Barakat, R., Curtin, J., Moore, M.A., Hoskins, W., Norton, L., Crown, J. (1995) Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. Journal of Clinical Oncology, 13, 1160 1166.
  • 5
    Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A., Jr, Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002 1006.
  • 6
    Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.-K., Pileri, S.A., Piris, M.A., Ralfkiaer, E., Warnke, R.A. (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361 1392.
  • 7
    Hryniuk, W. (1993) CHOP versus m-BACOD in non-Hodgkin's lymphoma. (Letter). New England Journal of Medicine, 328, 581.
  • 8
    Press, O., Leblanc, M., O'rourke, T., Gagnet, S., Chapman, R., Blacerzak, S., Fisher, R. (1998) Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphoma: Southwest Oncology Group Trial 9246. Journal of Clinical Oncology, 16, 574 578.
  • 9
    Rodriguez, M.A., Cabanillas, F.C., Velasquez, W., Hagemeister, F.B., McLaughlin, P., Swan, F., Romaguera, J.E. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology, 13, 1734 1741.
  • 10
    Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffier, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R.I., Gisselbrecht, C., Horning, S.J., Lepage, E., Lister, T.A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez, W.A., Yeap, B.Y. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987 994.
  • 11
    Tolcher, A.W., Cowan, K.H,., Noone, M.H., Denicoff, A.M., Kohler, D.R., Goldspiel, B.R., Barnes, C.S., McCabe, M., Gossard, M.R., Zujewski, J., O'shaughnessy, J.A. (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating actor in metastatic breast cancer patients. Journal of Clinical Oncology, 14, 95 102.
  • 12
    Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., Jagannath, S., Hagemeister, F.B., Redman, J.R., Swan, F., Barlogie, B. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117 122.
  • 13
    Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., Romaguera, J., Rubenstein, E., Cabanillas, F. (1994) ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology, 12, 1169 1176.
  • 14
    Wilson, W.H., Bryant, G., Bates, S., Fojo, A., Wittes, R.E, Steinberg, S.M., Kohler, D.R., Jaffe, E.S, Herdt, J., Cheson, B.D., Chabner, B.A. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 1573 1582.
  • 15
    Wilson, W.H., Chabner, B.A., Bryant, G., Bates, S., Fojo, A., Regis, J., Jaffe, E., Steinberg, S.M., Goldspiel, B.R., Cheson, B., Wittes, R.E. (1995) Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology, 13, 381 386.
  • 16
    Younes, A., Ayoub, J.P., Sarris, A., Hagemeister, F., North, L., Pate, O., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Kurzrock, R., Preti, A., Bachier, C., Smith, T., Cabanillas, F. (1997 a) Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology, 96, 328 332.
  • 17
    Younes, A., Ayoub, J.P., Sarris, A., North, L., Pate, O., McLaughlin, P., Rodriguez, A., Romaguera, J., Hagemeister, F., Bachier, C., Preti, A., Cabanillas, F. (1997 b) Paclitaxel (Taxol(R)) for the treatment of lymphoma. Annals of Oncology, 8, 129 131.